Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT06382948

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Led by MedSIR · Updated on 2026-04-03

240

Participants Needed

99

Research Sites

173 weeks

Total Duration

On this page

Sponsors

M

MedSIR

Lead Sponsor

S

Stemline Therapeutics, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Patients will be treated with elacestrant, a compound that acts as a selective estrogen receptor degrader, and everolimus (or placebo), a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer. The main purpose of the study is to analyze the efficacy (to find out how effective a treatment is) of elacestrant plus everolimus therapy in patients who have ER-positive/HER2-negative, ESR1-mutated, ABC progressing to endocrine therapy and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. The efficacy of elacestrant plus everolimus combination will be determined by assessing the period from elacestrant plus everolimus (or placebo) treatment initiation until to the first occurrence of disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason, whichever occurs first, defined as progression free survival. Rigorous eligibility criteria based on specific co-morbidities and clinicopathologic features of their disease have been designed to minimize the risk of patients participating in this study. The anticipated favorable clinical benefits of elacestrant combined with everolimus are projected to outweigh the risks of this treatment. This study will be performed in full compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and all applicable local Good Clinical Practice (GCP) and regulations.

CONDITIONS

Official Title

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able to understand the study and provide written informed consent.
  • Female or male patients aged 18 years or older.
  • Premenopausal or perimenopausal women must be receiving LHRH analogues for at least 28 days before randomization; postmenopausal women meet specific age or hormonal criteria.
  • Histologically or cytologically confirmed adenocarcinoma of the breast with unresectable locally recurrent or metastatic disease.
  • Tumor is estrogen receptor-positive (at least 10% positive cells) and HER2-negative as per guidelines.
  • ESR1 mutation status determined by validated tests before randomization.
  • Evidence of disease progression on prior CDK4/6 inhibitor and endocrine therapy after at least 6 months of treatment.
  • Received at least one and no more than two lines of endocrine therapy for advanced breast cancer.
  • No prior treatment with elacestrant or other investigational SERDs, PROTACs, CERANs, novel SERMs, or PI3K/AKT/mTOR inhibitors including everolimus for advanced disease.
  • No prior chemotherapy for advanced disease.
  • Presence of measurable or evaluable disease including bone-only disease with specific lesions.
  • Willingness to provide recent tumor tissue samples or archival tissue.
  • Fasting serum cholesterol ≤ 300 mg/dL and fasting triglycerides ≤ 2.5 times the upper limit of normal.
  • Adequate bone marrow, liver, kidney function, and coagulation status.
  • Resolution of acute toxic effects from prior cancer therapy to grade 1 or less.
  • Women of childbearing potential must have negative pregnancy test and agree to use effective contraception.
  • Male participants with partners of childbearing potential must use contraception or abstain.
  • ECOG performance status of 0 or 1.
  • Life expectancy of at least 12 weeks at screening.
Not Eligible

You will not qualify if you...

  • Unable to comply with study and follow-up procedures.
  • Contraindication to endocrine therapy such as visceral crisis or rapidly progressive visceral disease.
  • Currently participating in another therapeutic clinical trial.
  • Treatment with cancer therapy within 14 days before randomization except completed fulvestrant at least 28 days prior.
  • Active uncontrolled or symptomatic central nervous system metastases.
  • Intact uterus with history of certain endometrial lesions.
  • Other malignancies within 3 years except certain low-risk cancers.
  • Known allergy or hypersensitivity to study drugs.
  • Conditions interfering with pill swallowing or absorption.
  • Recent radiotherapy with wide field or significant bone marrow exposure.
  • Major surgery or significant injury within 14 days before randomization.
  • Significant cardiovascular or cerebrovascular disease within 6 months.
  • Uncontrolled atrial fibrillation or significant cardiac arrhythmias.
  • Severe pulmonary illnesses or conditions.
  • History or presence of interstitial lung disease or pneumonitis.
  • Recent coagulopathy or thrombotic events unless stable and treated.
  • Use of immunosuppressive agents or chronic corticosteroids except certain low doses or local uses.
  • Unable or unwilling to avoid medications or foods that affect CYP3A4 enzyme activity.
  • Pregnant or lactating women or unwillingness to use contraception.
  • Active infection with HIV, hepatitis B or C unless resolved as specified.
  • Known substance abuse or uncontrolled psychiatric or medical conditions contraindicating participation.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 99 locations

1

Medizinische Universität Innsbruck

Innsbruck, Austria

Actively Recruiting

2

Ordensklinikum Linz Barmherzige Schwestern

Linz, Austria

Actively Recruiting

3

Ordination Priv.-Doz. Dr. Michael Hubalek

Schwaz, Austria

Actively Recruiting

4

Medical University of Vienna

Vienna, Austria

Not Yet Recruiting

5

Tacchini Instituto de Pesquisa

Bento Gonçalves, Brazil

Not Yet Recruiting

6

Hospital Cachoeiro de Itapemirim

Cachoeiro de Itapemirim, Brazil

Not Yet Recruiting

7

Catarina Pesquisa Clínica - Neoplasias Litoral

Itajaí, Brazil

Not Yet Recruiting

8

UPCO - Hospital de Clinicas de Porto Alegre

Porto Alegre, Brazil

Not Yet Recruiting

9

NOB Ondina

Salvador, Brazil

Not Yet Recruiting

10

Masaryk Memorial Cancer Institute

Brno, Czechia

Actively Recruiting

11

Multiscan Nemocnice Horovice

Hořovice, Czechia

Actively Recruiting

12

University Hospital Olomouc

Olomouc, Czechia

Not Yet Recruiting

13

General University Hospital Prague

Prague, Czechia

Actively Recruiting

14

Tomas Bata Regional Hospital in Zlin

Zlín, Czechia

Actively Recruiting

15

Polyclinique Bordeaux Nord Aquitaine

Bordeau, France

Actively Recruiting

16

Institut Bergonié Bordeaux

Bordeaux, France

Not Yet Recruiting

17

Centre Georges François Leclerc

Dijon, France

Actively Recruiting

18

Centre Hospitalier de Limoges

Limoges, France

Actively Recruiting

19

CHU Lyon Sud

Lyon, France

Actively Recruiting

20

Institut Paoli Calmettes

Marseille, France

Not Yet Recruiting

21

APHP Tenon

Paris, France

Not Yet Recruiting

22

Hospital prive des Cotes d'Amor

Plérin, France

Actively Recruiting

23

CHU Saint Etienne

Saint-Priest-en-Jarez, France

Actively Recruiting

24

IUCT Oncopole

Toulouse, France

Actively Recruiting

25

Institute de Cancerologie de Lorraine - Nancy

Vandœuvre-lès-Nancy, France

Actively Recruiting

26

MVZ Klinikum Aschaffenburg

Aschaffenburg, Germany

Not Yet Recruiting

27

Hämatologie-Onkologie im Zentrum MVZ GmbH

Augsburg, Germany

Not Yet Recruiting

28

Städtisches Klinikum Dessau

Dessau, Germany

Not Yet Recruiting

29

Universitätsklinikum Dusseldorf

Düsseldorf, Germany

Not Yet Recruiting

30

Universitätsklinikum Essen

Essen, Germany

Not Yet Recruiting

31

MVZ II der Niels Stensen Kliniken

Georgsmarienhütte, Germany

Actively Recruiting

32

Klinikum Worms - Frauenklinik

Worms, Germany

Actively Recruiting

33

University General Hospital Alexandroupoli

Alexandroupoli, Greece

Actively Recruiting

34

251 Air Force General Hospital

Athens, Greece

Actively Recruiting

35

Aretaeio Hospital

Athens, Greece

Actively Recruiting

36

Attikon University Hospital

Athens, Greece

Actively Recruiting

37

Metropolitan General Hospital 4th department

Athens, Greece

Actively Recruiting

38

University General Hospital of Heraklion

Heraklion, Greece

Actively Recruiting

39

University General Hospital of Larissa

Larissa, Greece

Actively Recruiting

40

General University Hospital of Patras

Pátrai, Greece

Actively Recruiting

41

Metropolitan Hospital Greece 1st department

Piraeus, Greece

Actively Recruiting

42

EU Interbalkan Medical Center

Thessaloniki, Greece

Actively Recruiting

43

Cliniche Gavazzeni

Bergamo, Italy

Not Yet Recruiting

44

Azienda Ospedaliero-Universitaria (AOU) di Cagliari

Cagliari, Italy

Not Yet Recruiting

45

Aou Careggi

Florence, Italy

Actively Recruiting

46

IRCCS Ospedale Policlinico San Martino

Genova, Italy

Not Yet Recruiting

47

Ospedali Riuniti Livorno

Livorno, Italy

Actively Recruiting

48

Instituto Europeo di Oncologia

Milan, Italy

Actively Recruiting

49

AOU Policilinico Modena

Modena, Italy

Actively Recruiting

50

IRCCS San Gerardo

Monza, Italy

Not Yet Recruiting

51

Fondazione Pascale

Naples, Italy

Not Yet Recruiting

52

Azienda Ospedaliero- Universitaria Maggiore Della Carita

Novara, Italy

Actively Recruiting

53

Oncologia Medica AUSL Piacenza

Piacenza, Italy

Actively Recruiting

54

Policlinico A. Gemelli IRCCS

Roma, Italy

Not Yet Recruiting

55

Hospital Universitari Dexeus

Barcelona, Barcelona, Spain

Actively Recruiting

56

Centro Oncológico de Galicia

A Coruña, Spain

Actively Recruiting

57

Complejo Hospitalario Universitario de Santiago (CHUS)

A Coruña, Spain

Actively Recruiting

58

Hospital General Universitario Dr. Balmis (Alicante)

Alicante, Spain

Actively Recruiting

59

Hospital Universitario San Juan de Alicante

Alicante, Spain

Actively Recruiting

60

Institut Català d' Oncologia Badalona (ICO)

Badalona, Spain

Actively Recruiting

61

Hospital Clínic i Provincial de Barcelona

Barcelona, Spain

Actively Recruiting

62

Hospital del Mar

Barcelona, Spain

Actively Recruiting

63

Hospital Universitari Vall D'Hebron

Barcelona, Spain

Actively Recruiting

64

Hospital Universitario de Basurto

Bilbao, Spain

Actively Recruiting

65

Hospital Universitario de Burgos

Burgos, Spain

Actively Recruiting

66

Hospital Provincial de Castellón

Castellon, Spain

Actively Recruiting

67

Hospital San Pedro de Alcántara

Cáceres, Spain

Actively Recruiting

68

Hospital Universitario Clínico San Cecilio de Granada

Granada, Spain

Actively Recruiting

69

Complejo Hospitalario de Jaén

Jaén, Spain

Actively Recruiting

70

Hospital Universitario Insular de Gran Canaria

Las Palmas de Gran Canaria, Spain

Actively Recruiting

71

Hospital Universitario de León

León, Spain

Actively Recruiting

72

Hospital Universitario Arnau de Vilanova de Lleida

Lleida, Spain

Actively Recruiting

73

Hospital Beata María Ana

Madrid, Spain

Actively Recruiting

74

Hospital Universitario Doce de Octubre

Madrid, Spain

Actively Recruiting

75

Hospital Universitario La Paz

Madrid, Spain

Actively Recruiting

76

Hospital Universitario Puerta de Hierro Majadahonda

Madrid, Spain

Actively Recruiting

77

Hospital Universitario Ramón y Cajal

Madrid, Spain

Actively Recruiting

78

Hospital Universitario Sanchinarro-START-CIOCC

Madrid, Spain

Actively Recruiting

79

MD Anderson Cancer Center Madrid

Madrid, Spain

Actively Recruiting

80

Hospital Clínico Universitario Virgen de la Arrixaca

Murcia, Spain

Actively Recruiting

81

Hospital Universitari Son Espases

Palma de Mallorca, Spain

Actively Recruiting

82

Hospitalario Universitario de Navarra

Pamplona, Spain

Actively Recruiting

83

Hospital Universitario de Canarias

Santa Cruz de Tenerife, Spain

Actively Recruiting

84

Hospital Quirónsalud Sagrado Corazón

Seville, Spain

Actively Recruiting

85

Hospital Universitario Virgen del Rocío

Seville, Spain

Actively Recruiting

86

Hospital Universitario Virgen Macarena

Seville, Spain

Actively Recruiting

87

Hospital Universitari Sant Joan de Reus

Tarragona, Spain

Actively Recruiting

88

Hospital Universitario Marqués de Valdecilla

Valdecilla, Spain

Actively Recruiting

89

Consorci Hospital General Universitari de València

Valencia, Spain

Actively Recruiting

90

Hospital Arnau de Vilanova de Valencia

Valencia, Spain

Actively Recruiting

91

Hospital Clínico Universitario de Valencia

Valencia, Spain

Actively Recruiting

92

Hospital Universitario La Ribera - Alzira

Valencia, Spain

Actively Recruiting

93

Hospital Clínico Universitario Lozano Blesa

Zaragoza, Spain

Actively Recruiting

94

Western General Hospital

Edinburgh, United Kingdom

Not Yet Recruiting

95

Barts Health NHS Trust

London, United Kingdom

Actively Recruiting

96

Genesis Care Oxford

Oxford, United Kingdom

Actively Recruiting

97

Royal Surrey County Hospital

Surrey Quays, United Kingdom

Actively Recruiting

98

Royal Cornwall Hospital NHS Trust

Truro, United Kingdom

Actively Recruiting

99

Genesis Cancer Care UK

Waterlooville, United Kingdom

Actively Recruiting

Loading map...

Research Team

M

Medsir

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here